Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics, Inc. announced a global exclusive development and commercialization license agreement with Novartis to advance VAV1 molecular glue degraders, including MRT-6160. MRT-6160 is currently in an ongoing Phase I, single ascending dose/multiple ascending dose healthy volunteer study for immune-mediated conditions.